Citations

Clear

219 citation(s) found for "Do, Ron".

Prostate Health Index improves multivariable risk prediction of aggressive prostate cancer
Loeb, Stacy , Shin, Sanghyuk S. , Broyles, Dennis L., Wei, John T., Sanda, Martin G. , Klee, George G., Partin, Alan W. , Sokoll, Lori J. , Chan, Daniel W. , Bangma, Chris H. , Schaik, Ron H. N. van , Slawin, Kevin M., Marks, Leonard S. , Catàlona, William J. , Klee, George, Loeb, Stacy

Mayo Clinic

BJU International | October 15, 2016 | Volume: 120 | Issue: 1 | Pages: 61-68

10.1111/bju.13676 | PMID 27743489 Get It

Objective To examine the use of the Prostate Health Index ( PHI ) as a continuous variable in multivariable risk assessment for aggressive prostate cancer in a large multicentre US study. Materials and Methods The study population included 728 men, with prostate‐specific antigen ( PSA ) levels of 2–10 ng/ mL and a negative digital rectal examination, enrolled in a prospective, multi‐site early detection trial. The primary endpoint was aggressive prostate cancer, defined as biopsy Gleason score ≥7. First, we evaluated whether the addition of PHI improves the performance of currently available risk calculators (the Prostate Cancer Prevention Trial [ PCPT ] and European Randomised Study of Screening for Prostate Cancer [ ERSPC ] risk calculators). We also designed and internally validated a new PHI ‐based multivariable predictive model, and created a nomogram. Results Of 728 men undergoing biopsy, 118 (16.2%) had aggressive prostate cancer. The PHI predicted the risk of aggressive prostate cancer across the spectrum of values. Adding PHI significantly improved the predictive accuracy of the PCPT and ERSPC risk calculators for aggressive disease. A new model was created using age, previous biopsy, prostate volume, PSA and PHI , with an area under the curve of 0.746. The bootstrap‐corrected model showed good calibration with observed risk for aggressive prostate cancer and had net benefit on decision‐curve analysis. Conclusion Using PHI as part of multivariable risk assessment leads to a significant improvement in the detection of aggressive prostate cancer, potentially reducing harms from unnecessary prostate biopsy and overdiagnosis.
Responsiveness of 8 Patient‐Reported Outcomes Measurement Information System (PROMIS) measures in a large, community‐based cancer study cohort
Moinpour, Carol M. , Potosky, Arnold L. , Lobo, Tania , Hahn, Elizabeth A. , Hays, Ron D. , Cella, David , Keegan, Theresa H.M. , Paddock, Lisa E. , Stroup, Antoinette M. , Eton, David T. , Jensen, Roxanne E. , Smith, Ashley Wilder , Wu, Xiao‐Cheng

Mayo Clinic

Cancer | October 11, 2016 | Volume: 123 | Issue: 2 | Pages: 327-335

10.1002/cncr.30354 | PMID 27696377 Get It

BACKGROUND The Patient‐Reported Outcomes Measurement Information System (PROMIS) was a National Institutes of Health‐funded initiative to develop measures of symptoms and function. Responsiveness is the degree to which a measure can detect underlying changes over time. The objective of the current study was to document the responsiveness of 8 PROMIS measures in a large, population‐based cancer cohort. METHODS The Measuring Your Health study recruited 2968 patients who were diagnosed with 1 of 7 cancers between 2010 and 2012 through 4 Surveillance, Epidemiology, and End Results registries. Participants completed a baseline survey (6‐13 months after diagnosis) and a 6‐month follow‐up survey. Changes in 8 PROMIS scores were compared with global ratings of transition, changes in performance status, and clinical events. RESULTS Measures were responsive to 6‐month declines and improvements in performance status with small to large effect sizes (ES) (Cohen d = 0.34‐0.71; P < .01). Mean changes and effect sizes were larger for participants who reported declines compared with those who reported improvements. Small‐to‐medium ES were observed in patients who reported being “a little” worse (d = 0.31‐0.56), and medium‐to‐large ES were observed in those who reported being “a lot” worse (d = 0.53‐0.72). Hospitalized participants reported significant score increases, resulting in worsening of pain (d = 0.51), fatigue (d = 0.35), and depression (d = 0.57; all P < .01). Cancer recurrence and progression were associated with smaller increases in pain, fatigue, and sleep disturbance (d = 0.22‐0.27). CONCLUSIONS The current results indicated that all 8 PROMIS measures were sensitive to patient‐perceived worsening and improvement and to major clinical events. These findings will be able to inform the design and interpretation of future research studies and clinical initiatives administering PROMIS measures. Cancer 2017;123:327–335. © 2016 American Cancer Society .
Mechanisms Underlying the Pathogenesis of Isolated Impaired Glucose Tolerance in Humans
Varghese, Ron T. , Man, Chiara Dalla , Sharma, Anu , Viegas, Iván , Barosa, Cristina , Marques, Catía , Miles, John M., Rizza, Robert A., Jones, John G. , Dalla Man, Chiara, Shah, Mithun V , Miles, John M., Cobelli, Claudio , Vella, Adrian , Dalla Man, Chiara

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | September 7, 2016 | Volume: 101 | Issue: 12 | Pages: 4816-4824

10.1210/jc.2016-1998 | PMID 27603902 Get It

Context: Prediabetes is a heterogeneous disorder classified on the basis of fasting glucose concentrations and 2-hour glucose tolerance. Objective: We sought to determine the relative contributions of insulin secretion and action to the pathogenesis of isolated impaired glucose tolerance (IGT). Design: The study consisted of an oral glucose tolerance test and a euglycemic clamp performed in two cohorts matched for anthropometric characteristics and fasting glucose but discordant for glucose tolerance. Setting: An inpatient clinical research unit at an academic medical center. Patients or Other Participants: Twenty-five subjects who had normal fasting glucose (NFG) and normal glucose tolerance (NGT) and 19 NFG/IGT subjects participated in this study. Intervention(s): Subjects underwent a seven-sample oral glucose tolerance test and a 4-hour euglycemic, hyperinsulinemic clamp on separate occasions. Glucose turnover during the clamp was measured using tracers, and endogenous hormone secretion was inhibited by somatostatin. Main Outcome Measures: We sought to determine whether hepatic glucose metabolism, specifically the contribution of gluconeogenesis to endogenous glucose production, differed between subjects with NFG/NGT and those with NFG/IGT. Results: Endogenous glucose production did not differ between groups before or during the clamp. Insulin-stimulated glucose disappearance was lower in NFG/IGT (24.6 ± 2.2 vs 35.0 ± 3.6 μmol/kg/min; P = .03). The disposition index was decreased in NFG/IGT (681 ± 102 vs 2231 ± 413 × 10−14 dL/kg/min2 per pmol/L; P &lt; .001). Conclusions: We conclude that innate defects in the regulation of glycogenolysis and gluconeogenesis do not contribute to NFG/IGT. However, insulin-stimulated glucose disposal is impaired, exacerbating defects in β-cell function.
Minimum Information Required for a DMET Experiment Reporting
Kumuthini, Judit , Mbiyavanga, Mamana , Chimusa, Emile R. , Pathak, Jyotishman , Somervuo, Panu , Schaik, Ron HN van , Mizzi, Clint, Kalideen, Kusha, Ramesar, Raj , Maçek, Milan , Squassina, Alessio , Dolžan, Vita , Patrinos, George P. , Squassina, Alessio

Mayo Clinic

Pharmacogenomics | August 22, 2016 | Volume: 17 | Issue: 14 | Pages: 1533-1545

10.2217/pgs-2016-0015 | PMID 27548815 Get It

Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti‐HER2 targeted therapies
Gay, Laurie M. , Wang, Kai , Ali, Siraj M. , Chumsri, Saranya , Elvin, Julia A. , Bose, Ron , Vergilio, Jo‐Anne, Suh, James , Yelensky, Roman , Lipson, Doron , Chmielecki, Juliann , Waintraub, Stanley E., Leyland‐Jones, Brian , Miller, Vincent A. , Stephens, Philip J., Gay, Laurie M , Ross, Jeffrey S , Elvin, Julia A

Mayo Clinic

Cancer | June 10, 2016 | Volume: 122 | Issue: 17 | Pages: 2654-2662

10.1002/cncr.30102 | PMID 27284958 Get It

BACKGROUND Activating, nonamplification ERBB2 mutations ( ERBB2 mut) are not detected by immunohistochemistry (IHC) or fluorescence in situ hybridization (FISH), but are detected by DNA sequencing and may predict clinical responses to human epidermal growth factor receptor (HER2)‐targeted therapy. The authors queried 5605 advanced/metastatic breast cancers (mBC) to uncover the frequency of ERBB2 mut genomic alterations. Clinical responses to anti‐HER2 therapeutics were identified. METHODS DNA was extracted from 40 µm of formalin‐fixed paraffin‐embedded (FFPE) sections. Comprehensive genomic profiling (CGP) was used to evaluate up to 315 genes (592× mean coverage depth). Results were analyzed for base substitutions, short indels, copy number changes, and selected rearrangements. RESULTS Of 5605 cases, 698 (12.5%) featured ERBB2 alterations, including 596 (10.6%) ERBB2 amplifications ( ERBB2 amp) and 138 (2.4%) ERBB2 mut; 38 cases (0.7%) had co‐occurring ERBB2amp and ERBB2mut. ERBB2mut predominantly affected the kinase (124 cases; 90%) or extracellular (15 cases; 11%) domains. Both primary BC (52 cases; 38%) and metastatic site biopsies (86 cases; 62%) were found to harbor ERBB2 mut, which were distributed across carcinoma not otherwise specified (NOS) (69 cases; 50%), invasive ductal carcinoma (IDC) (40 cases; 29%), invasive lobular carcinoma (ILC) (27 cases; 20%), and mucinous mBC (2 cases; 1%). Genes commonly coaltered with ERBB2 were tumor protein 53 ( TP53 ) (49%); phosphatidylinositol 3‐kinase catalytic subunit alpha ( PIK3CA ) (42%); cadherin 1, type 1 ( CDH1 ) (37%); MYC (17%); and cyclin D1 protein ( CCND1 ) (16%). CDH1 mutations were enriched in ERBB2 mut mBC ( P <0.0006) and associated with recurrent mBC. Selected patients with ERBB2 mut, without ERBB2 amp, who responded to anti‐HER2 targeted therapies are presented herein. CONCLUSIONS Within this large series, 1.8% of cases harbored ERBB2 mut, which are undetectable by standard‐of‐care IHC or FISH tests. Metastatic BC driven by ERBB2 mut respond to anti‐HER2 targeted therapies, and expanding clinical trials designed to detect ERBB2 mut by CGP and optimize targeted treatments are warranted. Cancer 2016 . © 2016 American Cancer Society . Cancer 2016;122:2654–2662. © 2016 American Cancer Society.
Tolvaptan suppresses monocyte chemotactic protein-1 excretion in autosomal-dominant polycystic kidney disease
Grantham, Jared J. , Chapman, Arlene B., Blais, Jaime D., Czerwiec, Frank S., Devuyst, Olivier , Gansevoort, Ron T. , Higashihara, Eiji , Krasa, Holly B. , Zhou, Wen , Ouyang, John , Torres, Vicente E. , Investigators, for the TEMPO 3:4, Devuyst, Olivier; https://orcid.org/0000-0003-3744-4767 , Gansevoort, Ron T, Zhou, Wen, Perrone, Ronald D. , Torres, Vicente E

Mayo Clinic

Nephrology Dialysis Transplantation | April 15, 2016 | Volume: 32 | Issue: 6 | Pages: 969-975

10.1093/ndt/gfw060 | PMID 27190355 Get It

Abstract Background: Autosomal-dominant polycystic kidney disease (ADPKD) is characterized by multitudes of expanding renal cysts associated with mononuclear interstitial infiltrates. Monocyte chemotactic protein-1 is produced in the kidneys and excreted in the urine (uMCP1) of these patients in increased amounts. In the TEMPO 3:4 trial, tolvaptan slowed the rate of increase in total kidney volume (TKV) and the rate of decline in estimated glomerular filtration rate (eGFR). In a sub-analysis, we determined whether tolvaptan administration for up to 3 years changed the urinary excretion of MCP-1 referenced to creatinine in 869 treated subjects compared with 438 placebo subjects. Methods: Treatment group differences of uMCP1 at 0.75, 12, 24 and 36 months were evaluated by ANCOVA with factor of treatment and covariate baseline. Results: At baseline, mean uMCP1 was 429 ± 224 pg/mg in the tolvaptan and 434 ± 233 pg/mg in the placebo groups, ∼4-fold greater than normal. Log uMCP1 associated positively with log TKV (r = 0.2645, P &lt; 0.0001) and negatively with eGFR (r = −0.1555 P &lt; 0.0001) and fasting urine osmolality (r = −0.1933, P &lt; 0.0001). Tolvaptan reduced uMCP1 13.8 ± 4.4% (P &lt; 0.0001) below placebo-treated subjects at 24 months and 14.4 ± 3.7% (P &lt; 0.0001) at 36 months, and to the same extent in females and males. The effect of tolvaptan on uMCP1 excretion at 36 months extended across CKD Stage 1 (11.1 ± 6.4%, P = 0.0595), CKD 2 (13.9 ± 5.4%, P = 0.0050) and CKD 3 (21.4 ± 8.0%, P = 0.0020). Conclusion: Tolvaptan, administered for 3 years to patients with ADPKD, caused a sustained reduction in the urinary excretion of MCP-1 relative to placebo.
Scoring System Prognostic of Outcome in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome
Shaffer, Brian C. , Ahn, Kwang Woo , Hu, Zhen‐Huan , Malone, Adriana K. , Valcárcel, David , Hamilton, Betty K. , Kharfan‐Dabaja, Mohamed A. , Saad, Ayman , Warlick, Erica D. , Wirk, Baldeep , Sabloff, Mitchell , Fasan, Omotayo , Gerds, Aaron T. , Marks, David I. , Olsson, Richard F. , Wood, William A. , Costa, Luciano J. , Miller, Alan M. , Cortes, Jörge E. , Daly, Andrew , Kindwall‐Keller, Tamila L. , Kamble, Rammurti T., Rizzieri, David A. , Cahn, Jean‐Yves , William, Basem M. , Litzow, Mark R. , Wiernik, Peter H. , Vij, Ravi , Üstün, Celalettin , Copelan, Edward A. , Kalaycio, Matt, Alyea, Edwin P. , Sobecks, R., Pavletic, Steven Z. , Tallman, Martin S. , Saber, Wael , Nishihori, Taiga , Bacher, Ulrike , Hamilton, Betty, Kharfan-Dabaja, Mohamed A., Cutler, Corey, Warlick, Erica, Wirk, Baldeep Mona, Marks, David, Olsson, Richard, Wood, William Allen, Cortes, Jorge, Kindwall-Keller, Tamila L, Kamble, Rammurti, William, Basem, Savani, Bipin N. , Copelan, Edward, Popat, Uday, Maziarz, Richard, Alyea, Edwin, Sobecks, Ron, Pavletic, Steven, Tallman, Martin, Grunwald, Michael R. , Cutler, Corey S. , Reshef, Ran , Gale, Robert Peter , Liesveld, Jane L. , Popat, Uday R , Maziarz, Richard Thomas , Gerds, Aaron T , Saad, Ayman , Olsson, Richard F , Cortes, Jorge , William, Basem , Costa, Luciano J , Sabloff, Mitchell , Wood, William A , Valcárcel, David

Mayo Clinic

Journal of Clinical Oncology | April 5, 2016 | Volume: 34 | Issue: 16 | Pages: 1864-1871

10.1200/jco.2015.65.0515 | PMID 27044940 Get It

Purpose To develop a system prognostic of outcome in those undergoing allogeneic hematopoietic cell transplantation (allo HCT) for myelodysplastic syndrome (MDS). Patients and Methods We examined 2,133 patients with MDS undergoing HLA-matched (n = 1,728) or -mismatched (n = 405) allo HCT from 2000 to 2012. We used a Cox multivariable model to identify factors prognostic of mortality in a training subset (n = 1,151) of the HLA-matched cohort. A weighted score using these factors was assigned to the remaining patients undergoing HLA-matched allo HCT (validation cohort; n = 577) as well as to patients undergoing HLA-mismatched allo HCT. Results Blood blasts greater than 3% (hazard ratio [HR], 1.41; 95% CI, 1.08 to 1.85), platelets 50 × 109/L or less at transplantation (HR, 1.37; 95% CI, 1.18 to 1.61), Karnofsky performance status less than 90% (HR, 1.25; 95% CI, 1.06 to 1.28), comprehensive cytogenetic risk score of poor or very poor (HR, 1.43; 95% CI, 1.14 to 1.80), and age 30 to 49 years (HR, 1.60; 95% CI, 1.09 to 2.35) were associated with increased hazard of death and assigned 1 point in the scoring system. Monosomal karyotype (HR, 2.01; 95% CI, 1.65 to 2.45) and age 50 years or older (HR, 1.93; 95% CI, 1.36 to 2.83) were assigned 2 points. The 3-year overall survival after transplantation in patients with low (0 to 1 points), intermediate (2 to 3), high (4 to 5) and very high (≥ 6) scores was 71% (95% CI, 58% to 85%), 49% (95% CI, 42% to 56%), 41% (95% CI, 31% to 51%), and 25% (95% CI, 4% to 46%), respectively (P < .001). Increasing score was predictive of increased relapse (P < .001) and treatment-related mortality (P < .001) in the HLA-matched set and relapse (P < .001) in the HLA-mismatched cohort. Conclusion The proposed system is prognostic of outcome in patients undergoing HLA-matched and -mismatched allo HCT for MDS.
Diabetes-Associated Variation in TCF7L2 Is Not Associated With Hepatic or Extrahepatic Insulin Resistance
Varghese, Ron T. , Viegas, Iván , Barosa, Cristina , Marques, Catía , Rizza, Robert A., Jones, John G. , Shah, Mithun V , Vella, Adrian

Mayo Clinic

Diabetes | January 29, 2016 | Volume: 65 | Issue: 4 | Pages: 887-892

10.2337/db15-1593 | PMID 26822092 Get It

A common genetic variation in TCF7L2 is associated with type 2 diabetes. However, the mechanism by which this occurs remains elusive. In addition to affecting insulin secretion, genetic variation at the TCF7L2 locus may alter insulin action or directly modify hepatic glucose metabolism. We sought to determine whether the diabetes-associated variant in this locus (the T allele of rs7903146) increases fasting endogenous glucose production (EGP), and impairs insulin-induced suppression of EGP and insulin-stimulated glucose disappearance. To address this, we studied individuals who were either homozygous for the diabetes-associated allele (TT) at rs7903146 or were homozygous for the protective allele (CC). Subjects were matched for other anthropometric characteristics and were studied using a euglycemic clamp. EGP and glucose uptake were measured using the tracer dilution technique, and the relative contribution of gluconeogenesis to EGP was quantitated using deuterated water corrected for transaldolase exchange. We report that the diabetes-associated variation in TCF7L2 did not associate with fasting EGP, insulin-induced suppression of EGP, and insulin-induced stimulation of glucose uptake. There was no association with the contribution of gluconeogenesis and glycogenolysis to EGP. These data indicate that genetic variation at TCF7L2 does not predispose an individual to type 2 diabetes by altering either hepatic or extrahepatic insulin action.
TCF7L2 Genotype and α-Cell Function in Humans Without Diabetes
Varghese, Ron T. , Miles, John M., Piccinini, Francesca, Man, Chiara Dalla , Bailey, Kent R. , Rizza, Robert A., Shah, Mithun V , Miles, John M., Cobelli, Claudio , Vella, Adrian , Dalla Man, Chiara

Mayo Clinic

Diabetes | November 3, 2015 | Volume: 65 | Issue: 2 | Pages: 371-380

10.2337/db15-1233 | PMID 26525881 Get It

The diabetes-associated allele in TCF7L2 increases the rate of conversion to diabetes; however, the mechanism by which this occurs remains elusive. We hypothesized that the diabetes-associated allele in this locus (rs7903146) impairs insulin secretion and that this defect would be exacerbated by acute free fatty acid (FFA)–induced insulin resistance. We studied 120 individuals of whom one-half were homozygous for the diabetes-associated allele TT at rs7903146 and one-half were homozygous for the protective allele CC. After a screening examination during which glucose tolerance status was determined, subjects were studied on two occasions in random order while undergoing an oral challenge. During one study day, FFA was elevated by infusion of Intralipid plus heparin. On the other study day, subjects received the same amount of glycerol as present in the Intralipid infusion. β-Cell responsivity indices were estimated with the oral C-peptide minimal model. We report that β-cell responsivity was slightly impaired in the TT genotype group. Moreover, the hyperbolic relationship between insulin secretion and β-cell responsivity differed significantly between genotypes. Subjects also exhibited impaired suppression of glucagon after an oral challenge. These data imply that a genetic variant harbored within the TCF7L2 locus impairs glucose tolerance through effects on glucagon as well as on insulin secretion.